

BioSyent Inc.

Management's Discussion and Analysis

For the three and six months ended June 30, 2019 and 2018

August 22, 2019

Corporate Office
Suite 402
2476 Argentia Road
Mississauga, Ontario, L5N 6M1
Canada

Telephone 905.206.0013
Facsimile 905.206.1413

Email: info@biosyent.com
Web: www.biosyent.com



Table of Contents

1 INTRODUCTION

1 Forward-Looking Statements

1 Accounting Estimates and Accounting Policies

1 Non-IFRS Financial Measures

2 Overview, Vision, Strategy, and Products

2 Overview

2 BioSyent's Vision

2 BioSyent's Strategy

3 Evolution of Strategy

4 Pharmaceutical Business

6 Pharmaceutical Product Cycle

6 Pharmaceutical Product Pipeline

7 Pharmaceutical Business Structure

7 Legacy Business

8 New Capabilities and Awards

8 Key Performance Measures

9 Results of Operations for the three and six months ended June 30, 2019 and 2018

9 Sales

10 Sales Mix

12 Expenses

13 Net Income After Taxes (NIAT)

15 Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

16 Earnings per Share (EPS)

17 Financial Resources and Liquidity

18 Risk Management

23 Disclosure of Outstanding Share Data

23 Commitments

23 Office Leases

23 Purchase Commitments

24 Disclosure Controls

24 **Investor Relations Activities**

25 **Related Party Transactions**

25 Key Management Personnel Compensation

25 Transactions with Directors

25 **Legal Proceedings**

INTRODUCTION

The following discussion of BioSyent Inc.'s ("**BioSyent**" or the "**Company**") operations, performance and financial condition is based on the Company's interim unaudited condensed consolidated financial statements for the three and six months ended June 30, 2019 and June 30, 2018 ("**Consolidated Financial Statements**"), which were prepared in accordance with International Accounting Standard 34, Interim Financial

Reporting ("**IAS34**"). The discussion of financial condition and results of operations should be read in conjunction with the Consolidated Financial Statements, including the notes thereto. Additional information relating to the Company, including the Consolidated Financial Statements and the accompanying notes can be found at www.sedar.com.

Forward-Looking Statements

This management's discussion and analysis ("**MD&A**") contains or incorporates forward-looking statements within the meaning of Canadian securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, revenue, earnings, changes in costs and expenses, capital expenditures as well as changes in other objectives, strategic plans and business development goals, and may also include other statements that are predictive in nature or depend upon or refer to future events or conditions, and can generally be identified by words such as "may", "will", "expects", "anticipates", "intends", "plans", "believes", "estimates" or similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements are not historical facts, but instead represent only BioSyent's expectations, estimates, and projections regarding future events.

Although the Company believes the expectations reflected in such forward-looking statements are reasonable, such statements are not guarantees of future performance and involve certain risks and

uncertainties that are difficult to predict. Undue reliance should not be placed on such statements. Certain material assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Known and unknown factors could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Important assumptions, influencing factors, risks, and uncertainties are referred to in the body of this MD&A, in the press release announcing the Company's financial results for the three and six months ended June 30, 2019 and June 30, 2018 and in BioSyent's annual and interim financial statements and the notes thereto. These documents are available at www.sedar.com.

The forward-looking statements contained in this MD&A are made as at the date of this MD&A and, accordingly, are subject to change after such date. Except as required by law, BioSyent does not undertake any obligation to update or revise any forward-looking statements made or incorporated in this MD&A, whether as a result of new information, future events or otherwise.

Accounting Estimates and Accounting Policies

Effective as of January 1, 2019, the Company has adopted IFRS 16, *Leases* and has applied the requirements of IFRIC 23, *Uncertainty over Income Tax Treatments*. Please refer to Note 3 of the Consolidated Financial Statements for a summary of changes to the Company's accounting policies as well as recent accounting pronouncements impacting the Company.

The preparation of the Company's consolidated financial statements requires management to make critical judgments, estimates, and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the reporting date. On an ongoing basis, management evaluates its judgments, estimates, and assumptions

using historical experience and various other factors it believes to be reasonable under the given circumstances. In the future, actual experience may differ from these estimates and assumptions.

BioSyent's significant accounting judgments and estimates include recoverability of asset carrying values, impairment of trade and other receivables, income taxes, depreciation of equipment, amortization of intangible assets, share-based payments, inventory, and determination of the transaction price in revenue recognition. For a more detailed discussion of changes to the Company's critical accounting estimates, please refer to Note 4 of the Consolidated Financial Statements for the year ended December 31, 2018.

Non-IFRS Financial Measures

This MD&A makes reference to certain non-IFRS measures. These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are unlikely to be comparable to similar measures presented by other companies. When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure. These measures are provided as additional information

to complement those IFRS measures by providing a further understanding of the Company's results of operations from management's perspective.

Accordingly, these measures should not be considered in isolation nor as a substitute for analyses of the Company's financial information reported under IFRS. Management uses non-IFRS measures such as Earnings Before Interest, Taxes, Depreciation

and Amortization (“**EBITDA**”), Compound Annual Growth Rate (“**CAGR**”) and Trailing Twelve Months Earnings per Share (“**TTM EPS**”) to provide investors with supplemental measures of the Company’s operating performance and thus highlight trends in the Company’s core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also believes that securities analysts, investors, and other interested parties frequently use non-IFRS measures in the

evaluation of issuers. Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, and to assess the Company’s ability to meet future debt service, capital expenditure, and working capital requirements. The definition and a reconciliation of EBITDA, as used and presented by the Company, to the most directly comparable IFRS measures follows later in this MD&A.

Overview, Vision, Strategy, and Products

Overview

BioSyent is a publicly traded specialty pharmaceutical company which, through its wholly owned subsidiaries, BioSyent Pharma Inc. (“**BioSyent Pharma**”) and BioSyent Pharma International Inc., sources, acquires or in-licences and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd. and

Hedley Technologies (USA) Inc., also wholly owned subsidiaries of BioSyent, operate the Company’s legacy business, marketing biologically and health friendly non-chemical insecticides (the “**Legacy Business**”). BioSyent’s issued and outstanding common shares (the “**Common Shares**”) are listed for trading on the TSX Venture Exchange under the symbol “RX”.

BioSyent’s Vision

BioSyent’s vision is to be the leading independent Canadian healthcare company focused on commercializing innovative products improving patient lives and supporting healthcare providers.


BioSyent is independent and does not have access to large amounts of capital or a corporate pipeline of products funded by large investments in research and development. BioSyent is focused on innovative products that are sourced through international

partnerships. These products are unique due to manufacturing complexities, novel technologies, therapeutic advantages and/or strong, defensible intellectual property rights. The Company’s strategy allows it to commercialize these products as brands acquired or licensed to it by partners. The Company intends for its products to be differentiated and to improve patient lives. The Company works with, and supports, healthcare practitioners in achieving this objective.

BioSyent’s Strategy

BioSyent has four key elements to achieving its strategic objectives:

1. Expand the product portfolio
2. Build sales and marketing teams
3. Maximize revenue with international distribution
4. Maintain profitable growth



BioSyent has developed sourcing arrangements with partners based in the U.S. and Europe. The Company has a flexible format for such arrangements.

The Company seeks long-term buy-sell agreements or in-licensing arrangements with or without royalties or payments linked to milestone events such as regulatory approvals or reimbursement by formularies.

The Company exercises diligence when sourcing new products. Some of the steps in this process involve reviewing market data and market trends, interviewing key healthcare practitioners or medical advisory boards and obtaining opinions on reimbursement possibilities with payers. Once the Company has decided to proceed with a new product opportunity, it acquires or licenses exclusive Canadian and/or international market rights to that product. After the acquisition or in-licensing of the product, the Company manages the product through the regulatory and product registration process and, once approved, commercializes the product in Canada and/or international markets.

The Company uses various means of reducing risk in the marketplace. The Company adopts a gradually accelerating investment approach in promoting its products in the marketplace

by balancing its investment behind brands with brand revenue and growth and by segmenting the market into immediate and long-term growth opportunities. It pursues possible reimbursement avenues for its products in both the private and public sectors. The Company uses various marketing techniques throughout the product life cycle, as it deems appropriate, including healthcare practitioner detailing, direct to patient information, product differentiation materials, and expansion of patient and healthcare practitioner support services to increase awareness of product efficacy and safety. The Company employs a salesforce of qualified sales professionals across Canada with experience in pharmaceutical detailing to healthcare practitioners and hospitals.

The Company focuses on medications that occupy a niche in the market and are unique due to manufacturing complexities or novel technological and therapeutic advantages or are backed by strong partners holding defensible intellectual property rights. This strategy allows the Company to market these medications as brands it owns or licenses. By virtue of its strong growth record, the Company is able to attract partners for new products that have niche positioning.

Evolution of Strategy

The Company has not engaged in clinical trials due to the risks associated with such research activities. From time to time, the Company may acquire or in-license opportunities in late-stage development with which it, or its partners, have significant prior experience. Such experience and competency of the Company and its partners give the Company the ability to gauge risk in some depth. The Company may also seek in-licensing opportunities for new products launched in countries outside of Canada that require additional research and development work

before being launched in the Canadian market. The Company considers opportunities where there is a high probability that additional research and development work is likely to extend the lifecycle of portfolio products. Such studies might include in vitro or in vivo studies (including bio-equivalency studies, efficacy studies, or safety studies).

Pharmaceutical Business

FeraMAX® 150



In keeping with its strategy, the Company has, through BioSyent Pharma, launched FeraMAX® 150 to the Canadian healthcare market. FeraMAX® 150 is an

oral hematinic indicated for the prevention and treatment of iron deficiency anaemia. This non-ionic polysaccharide-iron complex formulation reduces adverse side effects common with other iron formulations. Shipments of FeraMAX® 150 commenced in April 2007.

FeraMAX® 150 continues to be a strong driver of growth in the Company's domestic and international pharmaceutical business. In 2015, the Company developed and launched a new Certified Vegan formulation of FeraMAX® 150. In 2016, the Company developed a 100mg formulation of FeraMAX® capsules ("FeraMAX® 100") for distribution in certain markets outside of Canada.

Cathejell®

Cathejell®

2% lidocaine hydrochloride jelly, USP

In July 2011, BioSyent Pharma received marketing approval from Health

Canada for Cathejell®. Cathejell® was in-licensed by BioSyent Pharma from Pharmazeutische Fabrik Montavit. Shipments of Cathejell® commenced in May 2012. In April 2017, BioSyent Pharma extended its in-license agreement with Pharmazeutische Fabrik Montavit, giving BioSyent Pharma exclusive Canadian rights to the Cathejell® product until March 31, 2024.

Cathejell® is an innovative pharmaceutical product that combines a sterile gel with lidocaine in a unique collapsible applicator syringe providing a safe and effective solution for patients to ease the discomfort of a range of medical procedures. Cathejell® is indicated for surface anesthesia and lubrication for various procedures including male and female cystoscopies, catheterizations and other endourethral operations, endoscopies, proctoscopies, rectoscopies, and tracheal intubations.

Cathejell® can also be used for the symptomatic treatment of pain in connection with cystitis and urethritis. Cathejell® has a unique collapsible syringe design with a trauma-free applicator tip that makes it easy to use for healthcare professionals and makes the application of the drug more comfortable for the subject patient.

FeraMAX® Powder



In July 2012, BioSyent Pharma received marketing approval from Health Canada for its unique new oral iron supplement

FeraMAX® Powder. FeraMAX® Powder is the only oral iron product available in Canada in a dissolvable powder and comes in pleasant tasting grape and raspberry flavoured crystals, which can be conveniently dosed by diluting them in water or mixing

them with soft foods. This innovative product is based upon the same non-ionic polysaccharide-iron complex technology found in FeraMAX® 150.

Other oral iron products made from common ferrous salts intended for infants and children either have an unpleasant heavy metallic taste which deters patient compliance, or they come in formulations containing alcohol which healthcare professionals and caregivers prefer to avoid. The Canadian market launch of FeraMAX® Powder in May 2013 was the global introduction of this product and provides BioSyent Pharma with a unique offering for international marketing partners. The Company has also launched the product in several international markets through distribution agreements.

Aguettant System®



In August 2012, BioSyent Pharma signed an exclusive Licensing and Distribution Agreement (the "**Aguettant Agreement**") with Laboratoire Aguettant S.A.S. ("**Laboratoire Aguettant**"). Pursuant to the Aguettant Agreement, the Company in-licensed three pre-filled syringe ("**PFS**")

products which are medical syringes pre-filled with a specific dosage of medication and marketed to hospitals and acute care settings.

The Aguettant System® for PFS offers a patented innovation that can be used for a variety of injectable medications. The Aguettant System® for PFS features a needleless, glassless, sterile plastic syringe with a ready-to-use dual tamper-evident seal. These products provide hospitals, clinics and healthcare professionals with improved patient safety as well as operational efficiencies.

Aguettant System® – Atropine Sulphate

One Aguettant System® urgent care product contains atropine sulphate, a commonly used drug in emergency situations and anaesthetic procedures. The Company launched this product in February 2015 as the first of three drugs for use in urgent care.

Aguettant System® – Phenylephrine Hydrochloride

In May 2016, the Company received approval from Health Canada for a new urgent care product, phenylephrine hydrochloride injection, for use in Aguettant System® PFS in hospitals and acute care settings. Phenylephrine hydrochloride injection is indicated for the treatment of clinically important hypotensive states, including overcoming peripheral vascular failure (shock, or shock-like states), maintenance of blood pressure in the setting of anesthesia, drug-induced hypotension, or hypersensitivity with circulatory compromise. The Company commenced distribution of this product in November 2016.

Regulatory work on a third urgent care PFS product was suspended by the Company in 2017.

RepaGyn®

RepaGyn®

In October 2013, the Company signed an exclusive Canadian Licensing and

Distribution Agreement with Farma-Derma s.r.l. (the “**RepaGyn Agreement**”). Pursuant to the RepaGyn Agreement, the Company distributes a women’s health product, RepaGyn®, which is an innovative vaginal suppository that has received approval from Health Canada. RepaGyn® helps relieve dryness and promotes healing of the vaginal mucosa. It is also recommended in situations where tissue repair is required after invasive vaginal surgeries and biopsy procedures. RepaGyn® vaginal suppositories can be used with or without local hormone therapy.

RepaGyn® is formulated with sodium hyaluronate, a naturally occurring compound, and offers a hormone-free treatment alternative proven to deliver symptom relief, restoration of pH balance and tissue repair all in one ovule.

RepaGyn® is supported by clinical evidence of both efficacy and symptom relief and has been recommended by doctors and successfully used by women in several European countries including Italy, France, Belgium, Switzerland, Denmark and Poland for over 10 years under the brand names Cicatridine®, Cicatridina®, Cikatrindina®, and Repadina®.

Proktis-M®

Proktis-M®

Rectal Suppositories • Sodium Hyaluronate

In March 2014, the Company entered into an in-licensing agreement for exclusive

marketing and distribution rights in Canada of Proktis-M® rectal suppositories with Farma-Derma s.r.l. Proktis-M® rectal suppositories are designed to help the healing of the anus and rectum. Proktis-M® rectal suppositories, which were launched by the Company in November 2014, have been studied and tested in conditions such as operated severe internal hemorrhoids, anal fissures, and prevention of radiation-induced proctitis.

Proktis-M® rectal suppositories are formulated with sodium hyaluronate, a naturally occurring compound, and offer a temporary matrix to facilitate cell proliferation which enhances wound healing. Proktis-M® rectal suppositories can be used on their own or in combination with other products. Proktis-M® rectal suppositories are supported by clinical evidence and have been successfully used to treat men and women in several European countries.

Cysview®

CYSVIEW®

HEXAMINOLEVULINATE HCL

In August 2015, BioSyent Pharma signed a Distribution and Supply Agreement with

Photocure ASA granting BioSyent Pharma an exclusive license to import, promote and sell the Cysview® product in Canada.

Cysview® is a patented, innovative technology that aids in the diagnosis and management of non-muscle-invasive bladder cancer. It is designed to selectively target malignant cells in the bladder and induce fluorescence during cystoscopic procedures using a blue-light enabled cystoscope.

This technology can lead to a 25% improvement in the detection of bladder cancer tumors as compared with traditional white light cystoscopy (Burger et al. 2013), leading to a reduced risk of recurrence. Cysview® has been successfully marketed in the U.S. and Europe and was approved by Health Canada in January 2015. The Company commenced the Canadian promotional launch of Cysview® in November 2015.

Tibella®

Tibella®

In November 2016, the Company signed an exclusive License and Supply Agreement with a European partner for a prescription product


in the women’s health therapeutic area for the Canadian market – Tibella®. Tibella® is a hormone replacement therapy (“HRT”) consisting of tibolone. Tibella® is indicated for the short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause. Tibolone has been approved and marketed in Europe for over 30 years and is also approved and marketed in other countries around the world. The Company received regulatory approval from Health Canada for Tibella® in May 2019 and is currently preparing for the launch of this product to the Canadian market. In Canada, Tibella® belongs in a sub-segment of the women’s health market valued at approximately CAD \$200 million (source: IQVIA market data for the 12 months ending December 2018).

Cardiovascular Products

In May 2016, the Company signed an exclusive Distribution Agreement with a European partner for two products in the cardiovascular therapeutic area for the Canadian market. The Company made a submission seeking marketing approval of the products in Canada in December 2017. Although these products have been approved in Europe and in certain other markets around the world, the Company received a Notice of Deficiency from Health Canada in respect of its regulatory submission in April 2019. In June 2019, as a result of the issues raised by Health Canada, the Company and its European partner decided to withdraw the regulatory submission for these two products. There are no current plans to take any further steps to obtain regulatory approval of these products in Canada.

Pharmaceutical Product Cycle

The Company organizes its product lifecycle into six stages: (i) the in-license stage, (ii) the regulatory stage, (iii) the pre-launch stage, (iv) the launch stage, (v) the growth stage, and (vi) the maturity stage.



The Company currently has eight products in the growth stage (FeraMAX® 150, Cathejell® FeraMAX® Powder, RepaGyn®, Cysview®, Aguettant System® Atropine and Phenylephrine, and Proktis-M®) and one product in the pre-launch stage (Tibella®).


Pharmaceutical Product Pipeline

The Company is committed to expanding its product portfolio and accelerating its product pipeline with a focus on innovative products that are unique. The Company is currently in discussions with several potential partners for new pharmaceutical product opportunities. Although launched in markets outside of Canada, some of these products may require some additional investment before the Company seeks approval from Health Canada for the Canadian market or other international government regulatory bodies for international markets.

Pharmaceutical Business Structure

The Company has three pharmaceutical business units: (i) the Community and Women’s Health Business Unit which commercializes pharmaceutical products focused on improving family and women’s health in Canada (the “**Community Business**”); (ii) the Hospital Business Unit which sells

pharmaceutical and healthcare products to Canadian hospitals and hospital specialists (the “**Hospital Business**”); and (iii) the International Pharmaceutical Business Unit which sells pharmaceutical products to markets outside of Canada (the “**International Business**”).



These three business units, collectively, the “**Pharmaceutical Business**”, are supported by the Company’s Corporate Operations, including the finance, supply chain and logistics, medical and regulatory affairs, information technology, business development, market access, human resources, business intelligence,

and legal functions. As the Company expands its product portfolio into new therapeutic areas, new specialty business units may be established as part of the pharmaceutical business structure as and when considered appropriate.

Legacy Business

Protect-It®

The Company continues to manufacture and market Protect-It®, a bio-friendly, non-chemical, food-safe grain insecticide. Protect-It® was developed through collaborative research between the Cereal Research Centre of Agriculture and Agri-Food Canada. Protect-It® is used as a preventative treatment against insect infestations in stored grains. The Legacy Business provides an additional source of recurring cash flows for the Company allowing it to focus on its strategic areas of growth in the Pharmaceutical Business.



New Capabilities and Awards

In May 2019, the Company's FeraMAX[®] brand was named the #1 Doctor and Pharmacist recommended over-the-counter oral iron supplement brand in Canada for the fourth consecutive year (*EnsembleIQ Healthcare Group: Pharmacy Practice + Business, The Medical Post, Profession Santé, CanadianHealthcareNetwork.ca, and ProfessionSanté.ca 2019 Survey on OTC Counselling and Recommendations*).



In 2019, the Company's FeraMAX[®] and RepaGyn[®] products were both recognized by the Society of Obstetricians and Gynaecologists of Canada (SOGC) in its Brand Recognition Program. Such SOGC recognition is granted to products that are found to safely and effectively promote female sexual and reproductive health; and/or general female well-being; and/or safe use during pregnancy. SOGC-recognized products are independently reviewed by a panel of medical professionals.



In May 2019, the Company received approval from Health Canada for Tibella[®], a prescription hormone replacement therapy ("HRT") consisting of tibolone. Tibella[®] substitutes for the loss of estrogen production in postmenopausal women and alleviates menopausal symptoms. This drug will form part of the Company's women's health product portfolio.



Key Performance Measures

Key performance measures for the second quarter ("Q2") ended June 30, 2019, 2018 and 2017 are summarized in the table below:

	Q2 2019	Q2 2018	Q2 2017	CAGR*
Sales	\$ 5,156,476	\$ 5,909,423	\$ 5,636,405	-4%
Sales Growth %	-13%	5%	29%	-
Net Income Before Taxes	\$ 903,063	\$ 2,118,540	\$ 2,003,227	-33%
Net Income Before Taxes Growth %	-57%	6%	44%	-
Net Income Before Taxes Margin	18%	36%	36%	-
Income Tax (Current and Deferred)	\$ 212,220	\$ 498,307	\$ 450,309	-
Net Income After Taxes	\$ 690,843	\$ 1,620,233	\$ 1,552,918	-33%
Net Income After Taxes Growth %	-57%	4%	53%	-
Net Income After Taxes Margin	13%	27%	28%	-
Net (Decrease) Increase in Cash and Short-term Investments	\$ (2,559,074)	\$ 1,374,553	\$ 658,030	-
Basic EPS	\$ 0.05	\$ 0.11	\$ 0.11	-
Diluted EPS	\$ 0.05	\$ 0.11	\$ 0.11	-

* CAGR - Compound Annual Growth Rate – See "Non-IFRS Financial Measures"

Sales CAGR between Q2 2017 and Q2 2019 was -4%. Net Income After Taxes CAGR was -33% between Q2 2017 and Q2 2019.

Key performance measures for the first half (“H1”) ended June 30, 2019, 2018 and 2017 are summarized in the table below:

	H1 2019	H1 2018	H1 2017	CAGR*
Sales	\$ 9,635,290	\$ 10,356,570	\$ 9,457,667	1%
Sales Growth %	-7%	10%	16%	-
Net Income Before Taxes	\$ 2,181,731	\$ 3,612,239	\$ 3,185,654	-17%
Net Income Before Taxes Growth %	-40%	13%	18%	-
Net Income Before Taxes Margin	23%	35%	34%	-
Income Tax (Current and Deferred)	\$ 512,707	\$ 848,876	\$ 731,180	-
Net Income After Taxes	\$ 1,669,024	\$ 2,763,363	\$ 2,454,474	-18%
Net Income After Taxes Growth %	-40%	13%	25%	-
Net Income After Taxes Margin	17%	27%	26%	-
Net (Decrease) Increase in Cash and Short-term Investments	\$ (4,525,242)	\$ 1,675,724	\$ 963,341	-
Basic EPS	\$ 0.12	\$ 0.19	\$ 0.17	-
Diluted EPS	\$ 0.12	\$ 0.19	\$ 0.17	-

Sales CAGR between H1 2017 and H1 2019 was 1%. Net Income After Taxes CAGR was -18% between H1 2017 and H1 2019.

Results of Operations for the three and six months ended June 30, 2019 and 2018

Sales

Sales Overview

Q2 2019 vs. Q2 2018

Total Company sales for Q2 2019 were \$5,156,476, decreasing 13% compared to total Company sales for Q2 2018 of \$5,909,423.

Canadian pharmaceutical sales for Q2 2019 were \$4,844,090, decreasing 4% compared to Canadian pharmaceutical sales for Q2 2018 of \$5,031,138.

International pharmaceutical sales for Q2 2019 were \$nil as compared to sales for Q2 2018 of \$511,483.

Legacy Business sales for Q2 2019 were \$312,386, decreasing 15% compared to Legacy Business sales for Q2 2018 of \$366,802.

H1 2019 vs. H1 2018

Total Company sales for H1 2019 were \$9,635,290, decreasing 7% compared to total Company sales for H1 2018 of \$10,356,570.

Canadian pharmaceutical sales for H1 2019 were \$9,114,230, increasing 4% compared to Canadian pharmaceutical sales for H1 2018 of \$8,796,776.

International pharmaceutical sales for H1 2019 were \$nil as compared to sales for H1 2018 of \$1,077,324.

Legacy Business sales for H1 2019 were \$521,060, increasing 8% compared to Legacy Business sales for H1 2018 of \$482,470.

Quarterly Sales Trend

Below is a summary of the Company’s sales by business for the eight most recently completed quarters:


	Q2 2019	Q1 2019	Q4 2018	Q3 2018	Q2 2018	Q1 2018	Q4 2017	Q3 2017
Sales								
Pharmaceutical Business (\$)	4,844,090	4,270,140	5,885,658	4,991,210	5,542,621	4,331,479	5,806,214	4,799,039
Growth% vs. prior year period	-13%	-1%	1%	4%	9%	19%	18%	15%
Legacy Business (\$)	312,386	208,674	25,307	268,283	366,802	115,668	95,274	604,561
Growth% vs. prior year period	-15%	80%	-73%	-56%	-35%	-31%	10%	4%
Total Sales (\$)	5,156,476	4,478,814	5,910,965	5,259,493	5,909,423	4,447,147	5,901,488	5,403,600
Growth% vs. prior year period	-13%	1%	0%	-3%	5%	16%	18%	13%

Sales Mix

The Pharmaceutical Business accounted for 95% of total sales in H1 2019 while the Legacy Business accounted for 5% of total sales. This sales mix is in line with management's focus on continuing to grow the Pharmaceutical Business while supporting the Legacy Business in a limited way.

Pharmaceutical Sales Trend

Pharmaceutical Sales By Quarter



Total pharmaceutical sales for Q2 2019 were \$4,844,090, decreasing 13% compared to total pharmaceutical sales for Q2 2018 of \$5,542,621, which increased 9% compared to Q2 2017. Q2 2019 pharmaceutical sales declined in both the Canadian and International pharmaceutical businesses compared to Q2 2018. Q2 2019 Canadian pharmaceutical sales declined by 4% versus Q2 2018. In the International Business, although the Company had recorded international sales in sixteen consecutive quarters to Q4 2018, \$nil sales were recorded in both Q1 2019 and Q2 2019 reducing H1 2019 pharmaceutical sales growth overall.

Canadian Pharmaceutical Sales Trend:

Q2 2019 vs. Q2 2018

Canadian pharmaceutical sales for Q2 2019 were \$4,844,090, decreasing 4% compared to Canadian pharmaceutical sales for Q2 2018 of \$5,031,138, which increased 16% compared to Q2 2017.

In the Community Business, Q2 2019 Canadian sales volumes (units) of FeraMAX[®] were flat compared to Q2 2018. Sales volumes (units) of the RepaGyn[®] product increased by 11% in Q2 2019 over Q2 2018.

In the Hospital Business, Q2 2019 Canadian sales volumes (units) of the Company's Cathejell[®] product declined by 22% versus Q2 2018 as a result of an increasingly competitive environment and a change in trade inventory management. Trade inventory also impacted sales volumes (units) of Aguettant System[®] PFS products during Q2 2019, which increased by 1% versus Q2 2018. Sales volumes (units) of the Company's growth-stage hospital product, Cysview[®], were lower in Q2 2019 versus Q2 2018 during which four of the nine currently operational hospital sites first went live with Cysview[®] and had placed initial orders.

H1 2019 vs. H1 2018

Canadian pharmaceutical sales for H1 2019 were \$9,114,230, increasing 4% compared to Canadian pharmaceutical sales for H1 2018 of \$8,796,776, which increased 14% compared to H1 2017.

In the Community Business, H1 2019 Canadian sales volumes (units) of FeraMAX[®] increased moderately as compared to H1 2018. Sales volumes (units) of the RepaGyn[®] product increased by 9% in H1 2019 over H1 2018.

In the Hospital Business, H1 2019 Canadian sales volumes (units) of the Company's Cathejell[®] product declined by 18% versus H1 2018. H1 2019 sales volumes (units) of Aguettant System[®] PFS products increased by 56% versus H1 2018 as a result of increased market penetration of the phenylephrine hydrochloride PFS product. Sales volumes (units) of Cysview[®] increased in H1 2019 as compared to a relatively low base in H1 2018. Although all nine currently operational hospital sites re-ordered Cysview[®] during H1 2019, the adoption and growth rate of this product have lagged management's expectations.

International Pharmaceutical Sales Trend:

Q2 2019 vs. Q2 2018

Pharmaceutical sales in the International Business for Q2 2019 were \$nil, as compared to sales for Q2 2018 of \$511,483, which decreased 31% compared to Q2 2017. Ongoing issues with trade

and currency restrictions in certain international markets persisted during Q2 2019, resulting in further delays in the timing of International FeraMAX[®] shipments.

H1 2019 vs. H1 2018

Pharmaceutical sales in the International Business for H1 2019 were \$nil, as compared to sales for H1 2018 of \$1,077,324, which increased 4% compared to H1 2017. In July 2019, subsequent to the reporting period, three international FeraMAX[®] orders, originally scheduled for shipment in H1 2019, were shipped to the Company's largest international customer. In spite of these recent international shipments and additional customer orders currently in process, the added transactional challenges of the International Business are expected to create continued near-term variability in the timing of international FeraMAX[®] shipments.

Legacy Business Sales Trend

Q2 2019 vs. Q2 2018

Legacy Business sales for Q2 2019 were \$312,386, decreasing by 15% compared to Legacy Business sales for Q2 2018 of \$366,802 which decreased by 35% compared to Q2 2017. While the Company's Canadian Protect-It[®] sales in Q2 2019 grew by 17% versus Q2 2018, sales to U.S. customers were \$nil in Q2 2019 as compared to sales of \$99,786 in Q2 2018, primarily as a result of wholesale inventory levels and a change in the distribution model for this product in the U.S. during the quarter.

H1 2019 vs. H1 2018

Legacy Business sales for H1 2019 were \$521,060, increasing by 8% compared to Legacy Business sales for H1 2018 of \$482,470 which decreased by 34% compared to H1 2017. The Company's Canadian Protect-It[®] sales grew by 36% in H1 2019 versus H1 2018, during which unfavourable growing conditions resulted in a delayed crop season. The Company did not record any Protect-It[®] sales to U.S. customers in H1 2019 as compared to U.S. sales of \$99,786 in H1 2018.

Legacy Business customers are generally less responsive to marketing and promotion, with demand for grain insecticides influenced more by weather conditions, prices of agricultural inputs, the quality and quantity of the food grain harvest, and the level of infestation of stored grain.

Expenses

Q2 2019 vs. Q2 2018

	Three months ended June 30,		% Change vs. Prior Period
	2019	2018	
Cost of goods sold	\$ 1,085,653	\$ 1,356,906	-20%
Selling and marketing	\$ 1,721,871	\$ 1,440,220	20%
General and administration	\$ 1,514,190	\$ 1,048,164	44%
New business development costs	\$ 21,833	\$ 25,190	-13%
Subtotal	\$ 4,343,547	\$ 3,870,480	12%
Finance income	\$ (90,134)	\$ (79,597)	13%

Largely as a result of a one-time impairment loss on intangible assets of \$424,941, total expenses, including the cost of goods sold ("COGS"), increased by 12% in Q2 2019 over the comparative period. Total expenses for Q2 2019 were \$4,343,547 as compared to total expenses for Q2 2018 of \$3,870,480. The ratio of total expenses to sales for Q2 2019 was 84%, higher than a ratio for Q2 2018 of 65%.

As a result of a decision in June 2019 to withdraw its regulatory submission to Health Canada for two cardiovascular pharmaceutical products, the Company incurred a one-time impairment loss on intangible assets of \$424,941. This one-time impairment loss, consisting primarily of regulatory filing costs, is included in general and administration expenses, which consequently increased by 44% in Q2 2019 versus Q2 2018.

Selling and marketing expenses for Q2 2019 of \$1,721,871 increased to a ratio of 33% of sales, as compared to 24% of sales in Q2 2018. During 2019, the Company increased its promotional spend on its products and made investments in its market intelligence software, data, and services in order to grow the Canadian market share of its products. As a result of these additional investments, advertising, promotion, and selling costs increased by 24% in Q2 2019 versus Q2 2018.

Q2 2019 finance income of \$90,134, consisting entirely of interest income, increased by 13% compared to finance income for Q2 2018 of \$79,597.

H1 2019 vs. H1 2018

	Six months ended June 30,		% Change vs. Prior Period
	2019	2018	
Cost of goods sold	\$ 2,044,077	\$ 2,387,800	-14%
Selling and marketing	\$ 3,093,686	\$ 2,648,982	17%
General and administration	\$ 2,499,891	\$ 2,006,247	25%
New business development costs	\$ 28,956	\$ 42,855	-32%
Subtotal	\$ 7,666,610	\$ 7,085,884	8%
Finance income	\$ (213,051)	\$ (341,553)	-38%

Total expenses for H1 2019 increased by 8% over the comparative period, impacted significantly by the one-time impairment loss on intangible assets of \$424,941. Total expenses for H1 2019 were \$7,666,610 as compared to total expenses for H1 2018 of \$7,085,884. The ratio of total expenses to sales for H1 2019 was 80%, higher than a ratio for H1 2018 of 68%.

General and administration expenses of \$2,499,891, including the \$424,941 impairment loss on cardiovascular products, increased by 25% in H1 2019 versus H1 2018. Consequently, general and administration expenses rose to a ratio of 26% of sales in H1 2019 as compared to 19% of sales in H1 2018.

Selling and marketing expenses of \$3,093,686 for H1 2019 increased by 17% as compared to H1 2018. Selling and marketing expenses were 32% of sales in H1 2019 as compared to 26% in H1 2018. During H1 2019, the Company expanded its field sales force, increased its media and promotional spends on growth stage products, and made significant investment in market intelligence

software and data. As a result, selling and marketing employee costs increased by 10% and advertising, promotion and selling costs increased by 20% in H1 2019 over the comparative period.


Finance income for H1 2019 was \$213,051, decreasing by 38% compared to H1 2018 finance income of \$341,553. While interest income increased by 58% in H1 2019 versus H1 2018 as the Company increased its yield on short-term GICs and other interest-bearing instruments, the Company did not realize any foreign exchange gains in H1 2019. By comparison, the Company realized \$206,500 in such foreign exchange gains in H1 2018 as a result of a higher level of foreign-currency denominated monetary assets held as well as greater variation in relevant foreign exchange rates during H1 2018 versus during H1 2019.

Net Income After Taxes (NIAT)

NIAT for Q2 2019 of \$690,843 decreased by 57% compared to NIAT for Q2 2018 of \$1,620,233 which increased by 4% compared to Q2 2017. This decrease in Q2 2019 NIAT was due primarily to delays in shipping international FeraMAX® orders and the one-time impairment loss incurred on cardiovascular products. To a lesser extent, NIAT was also impacted by incremental investment in selling and marketing in Q2 2019 versus Q2 2018.

The Company's NIAT margin for Q2 2019 was 13%, compared to a NIAT margin for Q2 2018 of 27%. Total Company sales decreased by 13% in Q2 2019 versus Q2 2018, while its operating expenses, including COGS, increased by 12% during this period, resulting in a lower NIAT margin for Q2 2019 overall.

Sales and Net Income Before & After Tax For the Quarter ended June 30




Including currency translation losses of \$35,742, total comprehensive income for Q2 2019 was \$655,101, decreasing by 59% compared to total comprehensive income for Q2 2018 of \$1,599,104.

NIAT for H1 2019 of \$1,669,024 decreased by 40% compared to NIAT for H1 2018 of \$2,763,363, which increased by 13% compared to H1 2017. This decrease in H1 2019 NIAT was due primarily to delays in shipping international FeraMAX® orders and the one-time impairment loss incurred on cardiovascular products. To a lesser extent, NIAT was also impacted by incremental investment in selling and marketing and a decline in realized foreign exchange gains in H1 2019 versus H1 2018.

The Company's NIAT margin for H1 2019 was 17%, compared to a NIAT margin for H1 2018 of 27%. Total Company sales decreased by 7% in H1 2019 versus H1 2018, while its operating expenses, including COGS, increased by 8% and its finance income decreased by 38% during this period, resulting in a lower NIAT margin for H1 2019 overall.

Sales and Net Income Before & After Tax For the First Half ended June 30




Including currency translation losses of \$12,164, total comprehensive income for H1 2019 was \$1,656,860, decreasing by 39% compared to total comprehensive income for H1 2018 of \$2,737,719.

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

EBITDA is a non-IFRS financial measure. The term EBITDA does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before

interest income or expense, income taxes, depreciation and amortization. A summary of the Company's EBITDA for the three and six months ended June 30, 2017, 2018, and 2019 is provided in the graph below:



EBITDA for Q2 2019 of \$860,259 decreased by 59% compared to EBITDA for Q2 2018 of \$2,088,638. This decline in EBITDA was due primarily to the decline in the Company's NIAT of 57% in Q2 2019 versus Q2 2018. A reconciliation of EBITDA to NIAT for the quarters ended June 30, 2019, 2018, and 2017 is provided in the table below:

RECONCILIATION OF EBITDA TO NIAT FOR THE QUARTER ENDED JUNE 30

	2019	2018	2017
Q2 EBITDA	\$ 860,259	\$ 2,088,638	\$ 2,023,234
Add: Interest Income	90,134	74,589	23,723
Less: Depreciation of Equipment	(23,058)	(20,303)	(20,537)
Amortization of Intangible Assets	(24,272)	(24,384)	(23,193)
Income Tax Expense	(212,220)	(498,307)	(450,309)
NIAT	\$ 690,843	\$ 1,620,233	\$ 1,552,918

EBITDA for H1 2019 of \$2,061,405 decreased by 42% compared to EBITDA for H1 2018 of \$3,566,405. This decline in EBITDA was due primarily to the decline in the Company's NIAT of 40% in H1 2019 versus H1 2018. A reconciliation of EBITDA to NIAT for the six months ended June 30, 2019, 2018, and 2017 is provided in the table below:

RECONCILIATION OF EBITDA TO NIAT FOR THE FIRST HALF ENDED JUNE 30

	2019	2018	2017
H1 EBITDA	\$ 2,061,405	\$ 3,566,405	\$ 3,214,558
Add: Interest Income	213,051	135,053	58,150
Less: Depreciation of Equipment	(44,181)	(40,223)	(41,075)
Amortization of Intangible Assets	(48,544)	(48,996)	(45,979)
Income Tax Expense	(512,707)	(848,876)	(731,180)
NIAT	\$ 1,669,024	\$ 2,763,363	\$ 2,454,474

Earnings per Share (EPS)

Below is a summary of the Company's quarterly sales, NIAT, and EPS for the eight most recently completed quarters:

	Q2 2019	Q1 2019	Q4 2018	Q3 2018	Q2 2018	Q1 2018	Q4 2017	Q3 2017
Sales (\$)	5,156,476	4,478,814	5,910,965	5,259,493	5,909,423	4,447,147	5,901,488	5,403,600
Net Income After Taxes (\$)	690,843	978,181	1,671,410	1,270,613	1,620,233	1,143,130	1,457,228	1,294,575
Earnings Per Share – Basic (\$)	0.05	0.07	0.11	0.09	0.11	0.08	0.10	0.09
Earnings Per Share – Diluted (\$)	0.05	0.07	0.11	0.09	0.11	0.08	0.10	0.09

Diluted EPS for Q2 2019 was \$0.05, decreasing by \$0.06 compared with diluted EPS for Q2 2018 of \$0.11. For the trailing twelve months (“TTM”) ended June 30, 2019, diluted EPS was \$0.32, decreasing by \$0.06 as compared to TTM diluted EPS of \$0.38 for period ended June 30, 2018.


Financial Resources and Liquidity

Working capital, defined here as the difference between current assets and current liabilities, decreased by 10% from \$25,138,174 as at December 31, 2018 to \$22,593,816 as at June 30, 2019. Cash and short-term investments of \$19,899,859 accounted for 88% of working capital as at June 30, 2019 compared to cash and short-term investments of \$24,425,101 accounting for 97% of working capital as at December 31, 2018. The Company generates sufficient cash and cash equivalents from its operations to supply the working capital it requires to meet its current growth and development activities.

During H1 2019, there was a net decrease in cash and short-term investments of \$4,525,242 compared to a net increase of \$1,675,724 during H1 2018. This decrease in cash and short-term investments was due primarily to \$4,627,490 expended during H1 2019 for the repurchase and cancellation of the Company's own common shares under a Normal Course Issuer Bid ("NCIB"). No such expenditure was made in the comparative period. Additionally, cash provided from operations declined to \$271,467 in H1 2019 as compared to \$1,979,280 in H1 2018.

The graph below illustrates the company's cash, cash equivalents and short-term investments as of June 30, 2017, 2018, and 2019 as well as the growth over the comparative prior year period:

Cash, Cash Equivalents and Short-term Investments at June 30



Total shareholders' equity decreased by 10% from \$27,605,662 at December 31, 2018 to \$24,805,060 at June 30, 2019. While the Company generated comprehensive income of \$1,656,860 during H1 2019, it repurchased 618,600 of its own common shares during the period under a NCIB, reducing shareholders' equity by \$4,593,464.

The Company's total assets at June 30, 2019 were \$28,043,303, representing a 10% decrease compared to total assets of \$31,188,491 as at December 31, 2018. This decrease in total assets was due primarily to a reduction in cash during the period from expenditure on NCIB share repurchases. This compares to an increase of 13% in total assets from \$25,104,848 at December 31, 2017 to \$28,313,610 as at June 30, 2018.

The Company has no short-term or long-term debt; however, the Company has credit facilities available with Royal Bank of Canada totaling \$3,090,000, including a foreign exchange facility of \$1,500,000, a credit card facility of \$90,000, and a revolving

demand credit facility of \$1,500,000 which had not been utilized as of June 30, 2019. This credit facility bears interest at a variable rate of Royal Bank prime plus 0.75% and has been secured with a General Security Agreement constituting a first ranking security interest of the Bank in the Company's property. The Company is subject to maintaining certain financial covenants if the demand credit facility is drawn upon. The Company has available additional foreign exchange facilities of \$2,500,000 with other Canadian financial institutions.

Risk Management

The Company's risk management policies and financial results are presided over by the Company's Audit Committee, which reports to the Board of Directors of the Company (the "Board"). The pharmaceutical industry in which the Company operates is exposed to several risks due to a strict regulatory environment, an enhanced level of quality consciousness, competition from generic drug companies and heightened intellectual property litigation. The Company cannot predict or identify all risk factors nor can it accurately predict the impact, if any, of the risk factors on its business operations or the extent to which a factor, event or any such combination may materially change future results of the Company's financial position from those reported or projected

in any forward-looking statements. Accordingly, the Company cautions the reader not to rely on reported financial information and forward-looking statements to predict actual future results.

This report and the accompanying financial information should be read in conjunction with this statement concerning risks and uncertainties. Some of the risks, uncertainties and events that may affect the Company, its business, operations and results are given in this section. However, the factors and uncertainties are not limited to those stated.

The Company has policies and practices mandated by the Board to manage the Company's risks. Such risks include the following:

1. Sourcing and Revenue Concentration

Some raw materials used in production are sourced from a single supplier and the Company is exposed to the same business risks that the supplier may experience. In line with

other pharmaceutical companies, the Company sells its products primarily through a limited number of wholesalers and retail pharmacy chains.

2. Foreign Exchange Risk

The Company currently earns revenue in Canadian dollars ("CAD"), U.S. dollars ("USD"), and Euros ("EUR") and incurs costs in Canadian dollars, U.S. dollars, and Euros. Management monitors the U.S. dollar and Euro net liability position on an ongoing basis during the period and adjusts the total net monetary liability balance accordingly. When it is appropriate to de-risk

future foreign exchange transactions, the Company uses Dual Currency Deposits and forward contracts to manage foreign exchange transaction exposure.

The following tables present foreign exchange sensitivity analyses for the assets and liabilities of the Company denominated in foreign currencies:

Foreign Exchange Sensitivity Analysis - USD

	June 30, 2019	December 31, 2018
Description of Asset/(Liability)	USD	USD
Cash and cash equivalents	47,273	418,338
Trade receivables	79,577	79,577
Less: Accounts payable	(478,069)	(609,106)
Net Total	(351,219)	(111,191)
Foreign Exchange Rate CAD per USD at the end of the period	1.3087	1.3642

At June 30, 2019, if the U.S. dollar had been stronger or weaker by 10% against the Canadian dollar with all other variables held constant, comprehensive income would have been \$33,783 lower or higher on an after-tax basis, respectively (December 31, 2018 - \$11,149 lower or higher, respectively).

Foreign Exchange Sensitivity Analysis - EUR

	June 30, 2019	December 31, 2018
Description of Asset/(Liability)	EUR	EUR
Cash and cash equivalents	350,820	505,166
Trade receivables	-	243,905
Less: Accounts payable	(169,038)	(211,734)
Net Total	181,782	537,337
Foreign Exchange Rate CAD per EUR at the end of the period	1.4887	1.5613

At June 30, 2019, if the Euro had been stronger or weaker by 10% against the Canadian dollar with all other variables held constant, comprehensive income would have been \$19,891 higher or lower on an after-tax basis, respectively (December 31, 2018 - \$61,663 higher or lower, respectively).

This foreign currency risk sensitivity analysis is unrepresentative of the risk inherent in receivables and payables in foreign exchange because the period-end exposure does not reflect the exposure during the period.

Forward Contracts:

The Company periodically enters into foreign exchange forward contracts to manage its foreign exchange risk on contracts denominated in U.S. dollars with financial institutions with investment grade credit ratings. Such contracts are classified as derivative financial instruments and measured at fair value through profit and loss. As at June 30, 2019, the Company entered into forward contracts to purchase up to a total of USD 1,020,000 and USD 1,530,000 (December 31, 2018 - USD 2,270,000 and USD 3,405,000) at exchange rates expressed in CAD per USD ranging from 1.2500 to 1.2600 which will be settled on various dates from July 2019 to November 2019. The Company's right to buy USD 1,020,000 on the respective settlement dates is subject to the spot

exchange rates on the settlement dates being below rates ranging from 1.3450 to 1.3500 CAD per USD. The Company's right to buy USD 1,530,000 on the respective settlement dates is subject to the spot exchange rates on the settlement dates being below rates ranging from 1.2200 to 1.2500 CAD per USD.

The fair value of forward exchange contracts is estimated based on quoted values from financial institutions. The Company's foreign exchange forward contracts resulted in a derivative asset of \$49,501 as at June 30, 2019 (December 31, 2018 - \$27,344).

Dual Currency Deposits:

The Company also invests in dual currency deposits ("DCD"). A DCD is a CAD or foreign currency denominated transaction that provides an enhanced guaranteed interest payment at maturity. However, the original denominated currency is converted to another specified currency at a specified exchange rate depending on whether the spot rate on the maturity date is above or below a specified fixed exchange rate. The fair value of DCDs is estimated based on quoted values from financial institutions.

As of June 30, 2019, the Company had CAD 2,500,000 in a CAD-USD dual currency deposit with a fair value of CAD 2,505,924. The fair value of dual currency deposits is estimated based on quoted values from financial institutions.

3. Interest Rate Risk

Cash flow interest rate risk is the risk that the future cash flow of a financial instrument will fluctuate because of changes in interest rates. Some of the Company's cash and cash equivalents as at the date of the Company's Consolidated Statements of Financial Position are invested in redeemable guaranteed investment certificates (each, a "GIC"), which earn interest at fixed rates during their tenure. The Company's short-term investments consist of non-redeemable GICs which also earn interest at fixed rates during their tenure. These GICs all have terms of one year or less.

The Company manages its interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations on a day-to-day basis. Fluctuations in market rates of interest when these GICs are renewed may have an impact on the Company's Finance Income for the period.

4. Credit Risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's cash and cash equivalents, short term investments, trade and other receivables, and loans receivable. The carrying amount of financial assets represents maximum credit exposure. As the Company invests in GICs with Canadian Chartered Banks, its credit risk on this account is negligible. The Company's loans receivable are full recourse and secured by a pledge of common shares of the Company purchased by the Borrowers, who are key management personnel. Based on these factors, the Company considers the

credit risk associated with these loans receivable to be low. There are no factors at period end to indicate a significant increase in credit risk has occurred and there are no defaults on the loans receivable.

a. Aging of Receivables

The majority of the Company's current customers are corporations with whom the Company has transacted for several years. None of these customers have defaulted in settling their liabilities to the Company. Based on its historical experience and customer base, the Company does not consider past due trade receivables to be impaired as of June 30, 2019.

Aged Trade Accounts Receivable	June 30, 2019	December 31, 2018
Current	\$ 2,152,282	\$ 1,386,339
Past due 1-30 days	332,386	570,614
Past due 31-60 days	79,127	47,108
Over 60 days	244,138	35,090
Closing Balance	\$ 2,807,933	\$ 2,039,151
Maximum Credit Risk	2,807,933	2,039,151

b. Concentration of Receivables

As of June 30, 2019, one customer represents 45% of trade receivables (December 31, 2018 - 27%) while another customer represents 20% of trade receivables (December 31, 2018 - 39%), and a third customer represents 15% of trade receivables (December 31, 2018 - 2%). There have been no past defaults by any of these three customers.

c. Loans Receivable

On December 8, 2016, the Board of Directors approved a Management Share Loan Program ("MSLP") under which the Company offered one-time, secured loans to certain management personnel employed by the Company (each a "Borrower") up to a maximum of fifty percent of each Borrower's base annual salary for the sole purpose of their purchase of the Company's issued and outstanding common shares at prevailing market prices through the facilities of the TSX Venture Exchange.

The Company advanced loan proceeds totaling \$391,500 on May 26, 2017, and a further \$175,000 on December 11, 2018, in accordance with the terms of the MSLP for the purchase of the Company's common shares by the Borrowers.

Each MSLP participant's loan (collectively, the "MSLP Participant Loans") bears interest at a rate of 1% - 2% per annum and is secured by a pledge of the common shares purchased under the MSLP by the Borrowers.

The MSLP Participant Loans are repayable by the Borrowers upon any sale of pledged shares by the Borrower in proportion to the then outstanding loan principal balance plus accrued interest. The remaining MSLP Participant Loan principal plus accrued interest must be fully repaid by the Borrowers no later than five years from

the date the loan proceeds were advanced (the "Maturity Date"), specifically, May 26, 2022 for loans advanced on May 26, 2017 and December 11, 2023 for loans advanced on December 11, 2018.

If a Borrower ceases to be employed by the Company prior to the end of the five-year Maturity Date, all outstanding loan obligations shall become due and payable on the 30th day following the date of termination. In addition, in the event of a default by the Borrower of the terms of the loan, the loan obligations will become due and payable immediately.

As the loans are full recourse loans, they have not been accounted for as stock-based compensation, but as financial instruments within the scope of IFRS 9, *Financial Instruments*.

d. Cash and Cash Equivalents and Short-term Investments

Cash, cash equivalents and short-term investments are maintained with Canadian financial institutions and the wholly owned subsidiaries of these financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and therefore bear minimal credit risk.

5. Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. Senior management is actively involved in the review and approval of planned expenditures. All contractual maturities of accounts payable and accrued liabilities are due within one year. The Company has no other liabilities.

The Company generates sufficient cash from operating activities to fund its operations and fulfill its obligations as they become due. The Company has credit facilities available with Royal Bank of Canada totalling \$3,090,000, including a revolving demand credit facility of \$1,500,000 which it has not drawn down as at the date hereof, a foreign exchange facility of \$1,500,000, and credit card facilities totalling \$90,000. The Company has available additional foreign exchange facilities of \$2,500,000 with other Canadian financial institutions. The Company's funds have not been committed in any way, except as set out in Note 17 of the Consolidated Financial Statements.

6. Information Technology (IT)

The integrity, reliability, and security of information in all forms are critical to the Company's operations and inaccurate, incomplete or unavailable information could lead to incorrect financial reporting, poor decisions, privacy breaches, and/ or inappropriate disclosure of sensitive information.

The Company is reliant on the integrity of its IT systems, hardware, software and certain other IT infrastructure in maintaining business continuity and in securing proprietary and sensitive information as well as certain of its financial assets. The Company has implemented comprehensive IT security policies and controls in order to safeguard its assets and sensitive information and to maintain business continuity in the event of potential disruptions. The integrity of the Company's IT systems

is exposed to a risk of malicious and unauthorized breaches by outside parties acting unlawfully. While extensive, the Company's IT security policies and controls cannot guarantee that such unauthorized breaches, whether targeted or opportunistic in nature, will not occur in the future. Such a breach could result in loss of financial assets through fraud, loss of sensitive information, reputational loss, or disruption of operations and business continuity.

The Company monitors its exposure to IT security risks on a continual basis and modifies its IT security policies, practices, infrastructure and insurance coverage as needed to address the assessed level of such risk.

7. Competition

The Pharmaceutical Business is characterized by intense competition and the Company is faced with the risk of enhanced competitive activity which may impact operational results.

8. Climatic Conditions

The Legacy Business is dependent on agricultural production which, in turn, is impacted by climatic variations which may affect demand for its products.

9. General Economic Conditions

The Company has no control over changes in inflation and interest rates, foreign currency exchange rates and controls or other economic factors affecting its businesses or the possibility of political unrest, legal or regulatory changes in jurisdictions in which the Company or its customers operate. These factors could negatively affect the Company's future results of operations.

10. Innovation

The competitiveness of the Company's products is subject to continuous innovation within the pharmaceutical industry. The Company tries to maintain the relevance of its products to the market but is exposed to new improved innovations that can undermine the competitiveness of its products.

11. Width of Product Portfolio

While the Company continuously strives to increase the portfolio of products in its commercialization pipeline, the high cost of acquiring new products and the long lead-time for bringing these products to market creates a dependency on a limited range of products at this time.

12. Agreements Relating to the Development and Distribution of Products

The Company currently has several collaboration or distribution agreements relating to the marketing and distribution of FeraMAX[®] products in international markets. The Company relies on these agreements because it does not wish to market its products directly in these markets.

The Company intends to secure additional agreements relating to the marketing and distribution of FeraMAX[®] and any other product for which it may receive commercial rights outside of Canada.

The Company may be unable to enter into in-licensing agreements for the development of new products and out-licensing agreements for the distribution of its existing products. The Company also faces and will continue to face, significant competition in seeking appropriate collaborators and marketing and distribution partners. Moreover, collaboration and distribution arrangements are complex and time-consuming to negotiate, document and implement.

Reliance on these agreements exposes the Company to a number of risks, including the following:

- Collaborators and marketing and distribution partners may not devote sufficient resources to the Company's products or product candidates;
- Disputes may arise with respect to payments that the Company believes are due under such distribution and collaboration agreements;
- Unwillingness on the part of collaborators and marketing and distribution partners to provide updates regarding the progress of its development, commercialization or marketing activities, or to permit public disclosure of these activities;

- Collaborators and marketing and distribution partners may terminate the relationship; disputes may arise in the future with respect to the ownership of rights to technology developed with collaborators;
- Disagreements with collaborators and marketing and distribution partners could result in litigation or arbitration;
- Collaborators may elect to pursue the development of any additional product candidates and pursue technologies or products either on their own or in collaboration with other parties, including competitors;
- Collaborators and marketing and distribution partners may pursue higher priority programs or change the focus of their programs, which could affect the collaborators' and marketing and distribution partners' commitment to their respective territories;
- Collaborators and marketing and distribution partners may develop or distribute products that compete with the Company's products; and
- The Company's pharmaceutical products are distributed to international markets where political and economic risks and uncertainties may exist. These risks and uncertainties could adversely affect the distribution of the Company's products to such markets.

The occurrence of any of these or other events may impair commercialization of the Company's products.

13. Regulatory Risks

With respect to BioSyent's Legacy Business, regulatory and legislative requirements affect the development, manufacture and distribution of BioSyent's products, including the testing and planting of seeds containing its biotechnology traits and the import of crops grown from those seeds. Non-compliance can harm sales and profitability. The failure to receive necessary permits or approvals could have near and long-term effects on BioSyent's ability to produce and sell some current and future products.

With respect to BioSyent's Pharmaceutical Business, the sale of pharmaceutical products is highly regulated, which significantly increases the difficulty and costs involved in obtaining and maintaining regulatory approval for marketing new and existing products.

Various business interruption risks inherent to the pharmaceutical industry, like product recalls, adverse drug reactions, quality issues and issues relating to good manufacturing practices may impact the financial results if they transgress regulatory boundaries.

The regulatory approval process can be long and may involve significant delays despite the Company's best efforts. There is also a risk that the Company's products may be withdrawn from the market and the required approvals suspended as a result of non-compliance with regulatory requirements.

Furthermore, there can be no assurance that the regulators will not require modification to any submissions, which may result in delays or failure to obtain regulatory approvals. Any delay or failure to obtain regulatory approvals could adversely affect the ability of the Company to utilize its technology, thereby adversely affecting

operations. Further, there can be no assurance that the Company's products will prove to be safe and effective in clinical trials or receive the requisite regulatory approval.

14. Specific Risks

The Company has insurance policies in place against risks relating to general commercial liability, product liability, product recall, loss of Company assets, IT security, and business interruption. The Company reviews its insurance coverage on a regular basis as part of its risk management program and adjusts this coverage

as appropriate, based its current risk profile and operations. The Company is exposed to the potential risk that claims made on the Company or losses incurred may be in excess of the level of insurance coverage undertaken by the Company.

Disclosure of Outstanding Share Data

The authorized share capital of the Company consists of 100,000,000 common shares without par value and 25,000,000 preferred shares without par value. The holders of the preferred shares as a class shall not be entitled to receive notice of, to attend or to vote at any meeting of the shareholders of the Company.

As at August 22, 2019, the following common shares and stock options were outstanding:

	No. of Shares	Exercise Price Range
Issued and outstanding common shares	13,814,677	
Stock options	177,512	\$6.20 - \$ 10.97
Fully Diluted at August 22, 2019	13,992,819	

Commitments

Office Leases

As of the date hereof, the Company had entered into two office lease agreements: One lease agreement extends to August 31, 2019 and the other lease agreement commences on September 1, 2019 and extends to August 31, 2029.

The Company's minimum future rental payments and occupancy costs for the next five fiscal years under these two lease agreements, are approximately as follows:

Fiscal Year	Annual Rent and Occupancy Cost
July – December 2019	\$ 151,887
2020	\$ 357,897
2021	\$ 357,897
2022	\$ 359,631
2023	\$ 363,100
Beyond Next 5 Fiscal Years	\$ 2,140,442

Short-term lease expense and cash outflow for leases for the six months ended June 30, 2019 was \$97,457.

Purchase Commitments

In the normal course of business, the Company has minimum purchase commitments with certain of its suppliers.

Disclosure Controls

The Company constantly endeavours to allow for greater segregation of duties and operating level controls within the constraints of its operating infrastructure. While intending to strengthen both these aspects of internal control, the Company believes that strong management supervisory controls minimize the possibility of erroneous financial reporting.

The certifying officers of the Company have opted not to certify the design and evaluation of the Company's disclosure controls and procedures ("**DC&P**") and internal control over financial reporting ("**ICFR**"). Inherent limitations on the ability of the certifying officers to design and implement (on a cost-effective basis) DC&P and ICFR for the Company may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.

Investor Relations Activities

Investor relations functions were accomplished through personnel whose duties include dissemination of news releases, investor communications and general day-to-day operations of the Company. Mr. René Goehrum, President and CEO, and Mr. Joost van der Mark, Vice President, Corporate Development, assist in the implementation of the Company's investor relations program.

Related Party Transactions

Key Management Personnel Compensation

The table below summarizes compensation for key management personnel of the Company for the three and six months ended June 30, 2019 and June 30, 2018:

	Three months ended June 30,		Six months ended June 30,	
	2019	2018	2019	2018
Number of Key Management Personnel	6	5	6	5
Salary, Benefits, and Bonus	\$293,606	\$245,622	\$587,212	\$491,244
Share-Based Payments	\$64,603	\$40,233	\$110,012	\$116,927

During the six months ended June 30, 2019, the Company recorded share-based payment expense of \$110,012 (six months ended June 30, 2018 - \$116,927) related to the vesting of options granted to key management personnel under the SOP as well

as the Company's contributions to the ESPP for the purchase of common shares on behalf of participating key management personnel.

Transactions with Directors

During the six months ended June 30, 2019, the Company paid total fees to its directors in the amount of \$71,300 (six months ended June 30, 2018 - \$61,950) and share-based payments of \$13,354 (six months ended June 30, 2018 - \$74,574).

Legal Proceedings

From time to time the Company may be exposed to claims and legal actions in the normal course of business. As of the date hereof, the Company was not aware of any litigation or threatened claims either outstanding or pending.